FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226537594> ?p ?o ?g. }

• W4226537594 endingPage "1506" @default.
• W4226537594 startingPage "1500" @default.
• W4226537594 abstract "PIK3CA and ESR1 mutations have been implicated in resistance to endocrine therapy (ET) in HR+, HER2- advanced breast cancer (ABC). Inhibition of CDK4 and 6 has been hypothesized as a therapeutic strategy to overcome endocrine resistance in patients with PIK3CA- or ESR1-mutant breast cancers. The objective of this exploratory analysis was to assess efficacy of abemaciclib plus fulvestrant in patients with or without PIK3CA or ESR1 mutations in MONARCH 2.MONARCH 2 was a global, randomized, double-blind phase III trial of abemaciclib plus fulvestrant in 669 women with HR+, HER2- ABC, which had progressed on ET. Patients were randomized 2:1 to receive abemaciclib plus fulvestrant or placebo plus fulvestrant. Exploratory analyses assessed progression-free survival (PFS) and overall survival (OS), and other endpoints, in patients with or without PIK3CA or ESR1 mutations detectable in baseline ctDNA.From the MONARCH 2 population, 219 and 248 patient samples were successfully analyzed for either PIK3CA or ESR1 mutations, respectively. Abemaciclib plus fulvestrant improved PFS compared with placebo plus fulvestrant in both PIK3CA-wild-type (median 16.9 months vs. 12.3 months; HR, 0.51; 95% CI, 0.33-0.78) and PIK3CA-mutant subgroups (median 17.1 months vs. 5.7 months; HR, 0.53; 95% CI, 0.33-0.84), as well as both ESR1-wild-type (median 15.3 months vs. 11.2 months; HR, 0.44; 95% CI, 0.27-0.71) and ESR1-mutant subgroups (median 20.7 months vs. 13.1 months; HR, 0.54; 95% CI, 0.37-0.79). Additional endpoints, including OS, were also improved following treatment with abemaciclib plus fulvestrant regardless of PIK3CA or ESR1 mutation status.Abemaciclib plus fulvestrant was effective regardless of PIK3CA or ESR1 mutation status, with benefit in both PFS and OS, with a numerically greater improvement in median PFS relative to placebo plus fulvestrant for PIK3CA- or ESR1-mutant tumors compared with the respective wild-type subgroups, in women with HR+, HER2- ABC that had progressed on ET." @default.
• W4226537594 created "2022-05-05" @default.
• W4226537594 creator A5004078969 @default.
• W4226537594 creator A5007579054 @default.
• W4226537594 creator A5013148496 @default.
• W4226537594 creator A5017506744 @default.
• W4226537594 creator A5021147423 @default.
• W4226537594 creator A5030451537 @default.
• W4226537594 creator A5048549140 @default.
• W4226537594 creator A5066769011 @default.
• W4226537594 creator A5069056507 @default.
• W4226537594 creator A5081153905 @default.
• W4226537594 creator A5090789911 @default.
• W4226537594 creator A5091245889 @default.
• W4226537594 date "2022-02-04" @default.
• W4226537594 modified "2023-10-17" @default.
• W4226537594 title "Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant" @default.
• W4226537594 cites W2021145743 @default.
• W4226537594 cites W2073367400 @default.
• W4226537594 cites W2159427817 @default.
• W4226537594 cites W2374277491 @default.
• W4226537594 cites W2415372857 @default.
• W4226537594 cites W2565707423 @default.
• W4226537594 cites W2604928956 @default.
• W4226537594 cites W2620993107 @default.
• W4226537594 cites W2767035762 @default.
• W4226537594 cites W2889646458 @default.
• W4226537594 cites W2896846857 @default.
• W4226537594 cites W2907884187 @default.
• W4226537594 cites W2945564879 @default.
• W4226537594 cites W2969690362 @default.
• W4226537594 cites W2976415870 @default.
• W4226537594 cites W3035496509 @default.
• W4226537594 cites W3083789602 @default.
• W4226537594 cites W3109453522 @default.
• W4226537594 cites W3120684612 @default.
• W4226537594 cites W3123151883 @default.
• W4226537594 cites W3166403155 @default.
• W4226537594 doi "https://doi.org/10.1158/1078-0432.ccr-21-3276" @default.
• W4226537594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35121623" @default.
• W4226537594 hasPublicationYear "2022" @default.
• W4226537594 type Work @default.
• W4226537594 citedByCount "26" @default.
• W4226537594 countsByYear W42265375942020 @default.
• W4226537594 countsByYear W42265375942022 @default.
• W4226537594 countsByYear W42265375942023 @default.
• W4226537594 crossrefType "journal-article" @default.
• W4226537594 hasAuthorship W4226537594A5004078969 @default.
• W4226537594 hasAuthorship W4226537594A5007579054 @default.
• W4226537594 hasAuthorship W4226537594A5013148496 @default.
• W4226537594 hasAuthorship W4226537594A5017506744 @default.
• W4226537594 hasAuthorship W4226537594A5021147423 @default.
• W4226537594 hasAuthorship W4226537594A5030451537 @default.
• W4226537594 hasAuthorship W4226537594A5048549140 @default.
• W4226537594 hasAuthorship W4226537594A5066769011 @default.
• W4226537594 hasAuthorship W4226537594A5069056507 @default.
• W4226537594 hasAuthorship W4226537594A5081153905 @default.
• W4226537594 hasAuthorship W4226537594A5090789911 @default.
• W4226537594 hasAuthorship W4226537594A5091245889 @default.
• W4226537594 hasBestOaLocation W42265375942 @default.
• W4226537594 hasConcept C121608353 @default.
• W4226537594 hasConcept C126322002 @default.
• W4226537594 hasConcept C142724271 @default.
• W4226537594 hasConcept C143998085 @default.
• W4226537594 hasConcept C204787440 @default.
• W4226537594 hasConcept C27081682 @default.
• W4226537594 hasConcept C2775930923 @default.
• W4226537594 hasConcept C2779744173 @default.
• W4226537594 hasConcept C2780482068 @default.
• W4226537594 hasConcept C2908647359 @default.
• W4226537594 hasConcept C530470458 @default.
• W4226537594 hasConcept C71924100 @default.
• W4226537594 hasConcept C84606932 @default.
• W4226537594 hasConcept C90924648 @default.
• W4226537594 hasConcept C99454951 @default.
• W4226537594 hasConceptScore W4226537594C121608353 @default.
• W4226537594 hasConceptScore W4226537594C126322002 @default.
• W4226537594 hasConceptScore W4226537594C142724271 @default.
• W4226537594 hasConceptScore W4226537594C143998085 @default.
• W4226537594 hasConceptScore W4226537594C204787440 @default.
• W4226537594 hasConceptScore W4226537594C27081682 @default.
• W4226537594 hasConceptScore W4226537594C2775930923 @default.
• W4226537594 hasConceptScore W4226537594C2779744173 @default.
• W4226537594 hasConceptScore W4226537594C2780482068 @default.
• W4226537594 hasConceptScore W4226537594C2908647359 @default.
• W4226537594 hasConceptScore W4226537594C530470458 @default.
• W4226537594 hasConceptScore W4226537594C71924100 @default.
• W4226537594 hasConceptScore W4226537594C84606932 @default.
• W4226537594 hasConceptScore W4226537594C90924648 @default.
• W4226537594 hasConceptScore W4226537594C99454951 @default.
• W4226537594 hasFunder F4320307758 @default.
• W4226537594 hasIssue "8" @default.
• W4226537594 hasLocation W42265375941 @default.
• W4226537594 hasLocation W42265375942 @default.
• W4226537594 hasLocation W42265375943 @default.
• W4226537594 hasLocation W42265375944 @default.
• W4226537594 hasOpenAccess W4226537594 @default.
• W4226537594 hasPrimaryLocation W42265375941 @default.

• next